Fmr LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

FMR LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 19.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,337,377 shares of the medical research company's stock after selling 1,540,082 shares during the quarter. FMR LLC owned about 1.66% of Thermo Fisher Scientific worth $3,296,893,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sepio Capital LP increased its stake in Thermo Fisher Scientific by 3.3% in the 4th quarter. Sepio Capital LP now owns 4,036 shares of the medical research company's stock worth $2,100,000 after acquiring an additional 130 shares during the last quarter. Quadrant Capital Group LLC raised its stake in Thermo Fisher Scientific by 4.4% during the fourth quarter. Quadrant Capital Group LLC now owns 5,322 shares of the medical research company's stock valued at $2,769,000 after purchasing an additional 224 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co lifted its position in Thermo Fisher Scientific by 33.4% during the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 63,900 shares of the medical research company's stock valued at $33,243,000 after purchasing an additional 16,000 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Thermo Fisher Scientific by 4.3% in the 4th quarter. Russell Investments Group Ltd. now owns 294,049 shares of the medical research company's stock worth $152,949,000 after buying an additional 12,212 shares during the last quarter. Finally, Hemenway Trust Co LLC raised its position in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. Hemenway Trust Co LLC now owns 5,408 shares of the medical research company's stock valued at $2,813,000 after buying an additional 156 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have weighed in on TMO. Raymond James reissued an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Morgan Stanley raised their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research note on Monday, February 3rd. Finally, Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $647.43.

Thermo Fisher Scientific Stock Up 2.5 %

Shares of Thermo Fisher Scientific stock traded up $10.61 during trading on Friday, hitting $438.05. 1,242,435 shares of the stock traded hands, compared to its average volume of 1,689,994. Thermo Fisher Scientific Inc. has a 52-week low of $409.85 and a 52-week high of $627.88. The stock's fifty day simple moving average is $513.41 and its 200 day simple moving average is $540.46. The firm has a market cap of $165.26 billion, a P/E ratio of 26.30, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last quarter. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.